Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530


Real-time Quote. Real-time Tradegate - 10/24 10:49:03 am
66.63 EUR   -0.58%
10/21 UCB : Transparency notification
10/10 UCB : Transparency notification
10/07 UCB : Transparency notification
News SummaryMost relevantAll newsSector news 

UCB : UCB’s Executive Committee with two new members

share with twitter share with LinkedIn share with facebook
share via e-mail
05/25/2011 | 07:15am CEST

• Greg Duncan, Executive Vice President, President of North American Operations

• Jean-Christophe Tellier, MD, Executive Vice President, President of European Operations

Vers la version en français

Naar de nederlandstalige versie

BRUSSELS, 25 May 07:00 (CET) - regulated information - With UCB set to enter its growth phase in 2012 and building on major advances in its late-stage pipeline, UCB announced today that two new members will join the company’s Executive Committee as of July 1, 2011.

The two new members are the heads of the US and European commercial operations, respectively Greg Duncan, currently Senior Vice President and President of UCB’s North American Operations, and Jean-Christophe Tellier, joining UCB from Ipsen.

These additions will allow Mark McDade, UCB’s EVP Global Operations and Chief Operating Officer to focus on UCB’s future growth markets outside the US and Europe, while driving UCB’s commercial growth strategy across all geographies. Mark will also continue to lead Business Development and maintains his global leadership of the company’s Marketing, Access and Medical Affairs functions, preparing the launch and commercialization of the next generation of medicines from UCB’s promising late-stage pipeline, such as brivaracetam in epilepsy, epratuzumab in Lupus and Sclerostin antibody in post-menopausal osteoporosis and fracture healing.

Greg Duncan joined UCB in 2007 to lead UCB’s European Operations. He then became President of European and Emerging Market Operations until 2009 when he was appointed President of UCB’s North American operations. Greg has a degree in Economics from the State University of New York, Albany, and a MBA in Marketing and Management from the Emory University in Atlanta. He started his career in 1989, within Pfizer, where he had spent 17 years holding various managerial positions. His last position within Pfizer was as President Latin America.

Jean-Christophe Tellier is joining UCB from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen’s specialty care business in North America, in the areas of endocrinology and neurology. Prior to joining Ipsen in May 2009, he was Executive Vice President and Chief Commercial Officer at MacroGenics Inc, a Maryland-based biotechnology company. Jean-Christophe Tellier spent the largest part of his career at Novartis (Ciba) where he held several commercial operations roles in France, Belgium and Switzerland. Jean-Christophe Tellier is a physician specialized in rheumatology (University of Paris V, France).

Detailed biographies of the members of the Executive Committee can be found on UCB’s website.

For further Information:

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712, Michael.tuck-sherman@ucb.comantje.witte@ucb.com

About UCB

UCB, Brussels, Belgium () is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9000 people in over 40 countries, UCB produced revenue of EUR 3.22 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.


UCB Media Room

e: UCB.MediaRoom@ucb.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on UCB
10/21 UCB : Transparency notification
10/10 UCB : Transparency notification
10/07 UCB : Transparency notification
10/03 UCB : CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpo..
09/29 UCB : Opens Solution Accelerator at Georgia Tech Technology Square
09/26 UCB : and Amgen announce U.S. FDA acceptance of biologics licence application fo..
09/26 UCB : Transparency notification
09/19 UCB : receives positive EU CHMP opinion for CIMZIA® (certolizumab pegol) AutoCli..
09/18 UCB : Results from phase 3 Frame study of romosozumab showed significant reducti..
09/16 UCB : Transparency notification
More news
Sector news : Pharmaceuticals - NEC
09:22a GSK files potential $1 billion shingles vaccine for U.S. approval
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/30 AMGEN GETS BUSY; MANY NEWS ITEMS : Anything Good Yet?
07/31 UCB S.A. 2016 Q1 - Results - Earnings Call Slides
07/31 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q2 2016 Results - Earnings Call ..
07/22 Amgen submits BLA in U.S. for osteoporosis candidate romosozumab
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
Financials (€)
Sales 2016 4 064 M
EBIT 2016 756 M
Net income 2016 471 M
Debt 2016 1 002 M
Yield 2016 1,88%
P/E ratio 2016 25,99
P/E ratio 2017 21,14
EV / Sales 2016 3,45x
EV / Sales 2017 3,17x
Capitalization 13 036 M
More Financials
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 79,0 €
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB-19.48%14 188
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.71%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results